The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses some of the recent trends in cancer ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

Sandeep Sahay, MD, FCCP, director of the Pulmonary Hypertension Program, Houston Methodist Hospital, previews key topics of ...

Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton ...

The CDC uses molecular cluster detection to find the transmission of HIV that could pinpoint where there are gaps in HIV care ...

Panelists discuss how the needs of older patients with spinal muscular atrophy (SMA) differ from infants, focusing on ...

Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing ...

Panelists discuss how spinal muscular atrophy (SMA) progresses over time, affecting motor function differently in older ...

Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond ...

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).